In 359 patients with acute ischaemic stroke without large/medium vessel occlusion and inadequate response to tenecteplase, IV tirofiban vs placebo raised excellent 90-day outcome (mRS 0-1) from 52.2% to 63.8% (RR 1.22). Symptomatic ICH: 0.9% vs 0%.
RCTn = 359
INSTANT Trial Authors for the INSTANT Investigators et al. Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial